Elevation Oncology, Inc. (ELEV) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Boston, NY, United States. El CEO actual es Joseph J. Ferra Jr..
ELEV tiene fecha de IPO 2021-06-25, 34 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $21.63M.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
